Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

INSPIRING CONFIDENCE
WITH THE WORLD'S
FIRST SELF-ADJUSTING
INSULIN PUMP SYSTEM

INSPIRING CONFIDENCE
WITH THE WORLD'S
FIRST SELF-ADJUSTING
INSULIN PUMP SYSTEM

Nicky time in range

DO YOUR PATIENTS KNOW ABOUT TIME IN RANGE?

Time in Range: The percentage of time glucose levels are between 3.9 -10 mmol/L, per unit of time.

Why it matters: More time in range means fewer severe highs and lows — and may result in a better quality of life.15,16

Clinical references
1. dQ&A Patient Panel. [Q4 2016 Summary Report]. dQ&A 2017. 2. American Diabetes Association. Promoting health and reducing disparities in populations. Standards of medical care in diabetes 2017. Diabetes Care. 2017;40(suppl 1):S6–S10 3. American Diabetes Association. Glycemic targets. Standards of medical care in diabetes 2017. Diabetes Care. 2017;40(suppl 1):S48–S56. 4. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type 1 and type 2 diabetes. Diabetologia. 2002;45(7):937-948. 5. Ayano-Takahara S, Ikeda K, Fujimoto S, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type1 diabetes. Diabetes Care. 2015;38(1):e1-e2. 6. Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407-1408. 7. Data On File. Medtronic Diabetes. Northridge, CA. 8. Data On File. Medtronic Diabetes. Northridge, CA. Continued access phase HCP interview notes. 9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes management. N Engl J Med. 1993;329(14):977-986. 10. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009; 32(8):1378-1383. 11. Bergenstal R, Tamborlane W, Ahmann A, et al. Effectiveness of sensor-augmented insulin pump therapy in type 1 diabetes. N Engl J Med. 2010; 363(4): 311-320. 12. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections. JAMA. 2017;317(4):371-378. 13. Bailey T, Wallace JF, Greene, C et al. Accuracy and user performance evaluation of the CONTOUR®NEXT LINK 2.4 blood glucose monitoring system. Clin Chim Acta. 2015; 448:139 -145. 14. Data On File. Medtronic Diabetes. Northridge, CA. Patient survey of pivotal patients. 15. Vanstone, M, Rewegan, A, Brundisini, F, et al. Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: A systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2015; 15(17): 1–29. 16. Ayano-Takahara, S, Ikeda, K, Fujimoto, S, Hamasaki, A, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2015 Jan; 38(1): e1-e 17.Customer Training Phase-Data on File. 2. Priority Access Phase-Data on File (n>13,000)
*ADA glycemic recommendation for non-pregnant adults. More or less stringent glycemic goals may be appropriate for individual patients. An A1C goal of 7.5% is recommended across all pediatric age-groups. **Refers to SmartGuard™ Auto Mode feature; The MiniMed™ 670G System can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 4.4-10 mmol/"L in non-pregnant adults with diabetes. Based on clinical study data in pivotal trial. Individual results may vary. § Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. Do not calibrate your CGM device or calculate a bolus using a
blood glucose meter result taken from an alternative site testing (palm) or from a control solution test.
Indications
The MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons age seven and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM), and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
Warnings
Important Safety Information: MiniMed™ 670G System

The safety of using Auto Mode, Suspend before low, and Suspend on low in people who have no pump experience is not known. Auto Mode, Suspend before low, and Suspend on low should not be used if insulin pump settings have not been previously established. Insulin pump settings include basal rates, insulin to carb ratio, or insulin sensitivity factors. Always discuss with your healthcare professional before using Auto Mode, Suspend before low, or Suspend on low.
Do not make treatment decisions, such as determining your insulin dose for meals, using the MiniMed 670G system CGM values, as they are not intended to be used to make such treatment decisions. The MiniMed 670G system CGM does not replace a BG meter. Always use the values from your BG meter for treatment decisions. BG values may differ from SG values. Using the SG readings for treatment decisions could lead to high or low BG.
Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycaemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.
The MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons age seven and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM), and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
Contraindications
Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Important Update for Australian MiniMed Pump users. Learn More